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Abstract
Background: Up to 71% of trauma victims diagnosed with PTSD have frequent nightmares (NM), compared to only 2% to 5% of the
general population.
Objectives: The present study examined whether nightmares before the beginning of cognitive behavior therapy (CBT) for post-
traumatic stress disorder (PTSD) could influence overall PTSD symptom reduction for 71 individuals with PTSD and different types
of traumatic events.
Patients and Methods: Participants received a validated CBT of 20 weekly individual sessions. They were evaluated at five measure-
ment times: at pre-treatment, after the third and ninth session, at post-treatment, and at 6 months follow-up.
Results: The presence of nightmares did not impact overall CBT efficiency. Specific CBT components were efficient in reducing the
frequency and distress of nightmares.
Conclusions: Most participants no longer had PTSD but some still had nightmares.
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1. Background
Up to 71% of trauma victims diagnosed with PTSD have
frequent nightmares (NM), compared to only 2% to 5% of
the general population (1). Empirical findings showed that
NM before a traumatic event could contribute to the devel-
opment and the maintenance of PTSD symptoms (1), that
they were associated with depression (2), that they reduced
sleep quality (3), and that they were not specific to one type
of trauma, although they were often reported by combat
veterans and victims of sexual assault (4).
To date, the treatment recommended by the interna-
tional society for traumatic stress studies for overall PTSD
symptoms is trauma-focused cognitive behavioral therapy
(CBT) (5, 6). According to the rationale of trauma-focused
cognitive behavioral therapy (CBT), traumatic events can
contribute to create a memory network called the fear
structure and the dysfunctional connections of that struc-
ture can be modified through imaginal or in vivo exposure
(5). According to this model, NM are considered to be one
element of the fear structure and are thus perceived as a
symptom of re-experience that simply occurs at night. If
that was the case, NM should no longer be present when
PTSD is successfully treated. However, some studies have
indicated that NM persisted in a clinically significant man-
ner after CBT (e.g. (7, 8)).
Studies have generally examined the global impact of
CBT as a whole on NM reduction. However, CBT is a multi-
component treatment and the effect of its various strate-
gies on sleep can vary. A study from Salcioglu et al. (9)
tested the efficacy of in vivo exposure with 59 survivors of
an earthquake. Although NM were significantly reduced af-
ter this intervention, they remained a clinically significant
symptom. In a more recent study (7), the efficacy of cog-
nitive processing therapy (CPT) and prolonged exposure
(PE) were compared among female rape victims with PTSD.
Both CPT and PE had large effects on NM reduction, but nei-
ther of them achieved complete NM remission.
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Studies reporting NM before and after CBT in a trau-
matic context are rare (10) and studies monitoring the im-
pact of individual CBT strategies for PTSD on NM using val-
idated instruments are even more limited. No study has
investigated the impact of NM on CBT for PTSD efficacy.
Such research would help clarify the potential role of NM
in PTSD remission and assess the need to include a specific
NM intervention in PTSD treatment.
2. Objectives
The objectives were to determine whether the presence
of NM before the beginning of CBT for PTSD influences
PTSD symptom reduction and to examine the efficacy of
each CBT strategy on NM reduction.
3. Patients and Methods
This study’s prospective, longitudinal and repeated
measures design (11) was conducted on participants re-
ferred to the trauma studies centre of the institut univer-
sitaire en sante mentale de montreal (IUSMM) in Canada.
The ethics committee of the IUSMM approved this research
project. All participants (n = 71) signed an informed con-
sent. Inclusion criteria were: a) to be aged between 18
and 65 years old; b) to have been exposed to at least one
traumatic event in adulthood; c) to present PTSD as a pri-
mary diagnosis according to the DSM-IV-TR (12). The ex-
clusion criteria were: a) repeated war-related traumas; b)
alcohol or substance abuse/dependence; c) active suici-
dal ideations, d) past or present psychotic episode, e) past
or present psychotic episode, bipolar disorder, or organic
mental disorder, f) ongoing threat (e.g., continued harass-
ment) and g) overwhelming personal problems (e.g., atten-
dance to a trial); and h) severe personality disorder. Par-
ticipants were asked to refrain from adjusting their psy-
chotropic medication and to refrain from engaging in an
additional psychotherapy.
Participants were assessed five times: before the begin-
ning of the treatment (pre-treatment), after the psychoed-
ucation and diaphragmatic breathing component (3rd ses-
sion; T1), after the imaginal exposure component (9th ses-
sion; T2), at the end of the treatment (post-treatment), and
at 6-months follow-up.
The empirically validated CBT for PTSD protocol (5, 13)
consisted of 20 weekly individual sessions of 90 minutes.
Sessions one to three were characterized by psychoeduca-
tion regarding PTSD symptoms and anxiety management
strategies focused on diaphragmatic breathing. Sessions
four to nine consisted of practice imaginal exposure to
memories of the traumatic event with cognitive restruc-
turing if necessary. Sessions 10 to 20 were in vivo exposure
to avoided situations and relapse prevention. Participants
received a manual and therapists followed a standardized
intervention protocol.
3.3. Measurement
Participants completed the structured clinical inter-
view for DSM-IV-TR Axis I disorders (SCID-I) (14). They also
completed the life events checklist (LEC; (15)) to screen for
potentially traumatic events. PTSD severity was evaluated
by the clinician-administered PTSD scale (CAPS) (16). The
frequency and distress of the B2 item were retrieved from
the CAPS and used to determine NM presence (frequency)
and distress. All questionnaires demonstrate good psycho-
metric properties.
3.4. Statistical Analysis
Data were analyzed using SPSS v.17.0 software. The five
measurement times were included in the analysis. No dif-
ferences between completers and non-completers were ob-
served on the sociodemographic variables (except for edu-
cation: X2 (1, 87) = 8.17, P < .05), and severity of the CAPS
symptoms.
Because the CAPS-B2 item (frequency and distress) did
not meet the normality hypothesis, it was dichotomized as
0 (= no symptoms or mild symptoms; that is, a score of 0 or
1 on the CAPS) and 1 (= presence of symptoms; which corre-
sponds to a score of 2, 3 or 4).
Because all the correlations between age, sex and time
since the event and the different dependant variables were
not significant, they were not included in the analyses.
Data analyses were performed using descriptive statistics
(frequency, mean and standard deviation for each variable)
and inferential statistics (ANOVA, t-test, chi-square, non-
parametric Cochran’s Q tests, pairwise comparisons using
continuity-corrected McNemar’s tests with Bonferroni cor-
rection). When the assumption of sphericity is violated for
the ANOVA, the Greenhouse-Geisser correction will be con-
sidered. The significance level was set at 0.05 for each test.
3.5. Ethical Consideration
Participants did not receive any financial compensa-
tion.
4. Results
Perfect (100%) inter-rater agreements were obtained
for the evaluations at pre-test, and 91.3% at post-test for
the PTSD diagnosis. At baseline, inter-rater agreement was
computed based on 34% of the completers and 31% of the
non-completers. At post-treatment, it was calculated based
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on 32% of the completers. Therapeutic integrity was also
good, with 99.6% agreement.
The recruitment chart is presented in Figure 1. A total
of 71 participants completed the treatment, and 5 partici-
pants were lost at 6 months follow-up. The attrition rate
was 18.4%.
217 Participants Attended in-
Person Clinical Evaluation for
Eligibility
89 Participants Met Inclusion Criteria
2 Participants Refused to
Participate to the Research Project
5 Participants Lost at 6 Months
Follow-up
16 Participants Abandoned:
-11 did not Need
the Therapy
Anymore





87 Participants Began the Treatment
71 Participants Completed the
Treatment
66 Participants Evaluated at
6 Months Follow-up
Figure 1. Flowchart of Participents
Most participants (64.8%) were women, and mean
age was 38.65 years (SD = 1.35) (see Table 1). Baseline
CAPS mean score was 78.58 (SD = 13.08), suggesting high
symptom severity. Participants reported four main cate-
gories of trauma associated with their current PTSD: phys-
ical harm (48%); accident/catastrophe (31%); death-related
stress (18%); and others (3%). The average time interval
since trauma was two years (SD = 3.97). Most participants
(70.3%) reported NM related to their traumatic event at pre-
treatment.
Table 1. Baseline Characteristics of Completers Samplea
Characteristics N (%) Mean± SD




Married or Common-Law Relationship 31 (43.70)
Employment Status
Employed 19 (26.80)









Physical Harm 34 (47.90)
Death-Related Stress 13 (18.30)
Other 2 (2.80)
Time Interval Since Trauma (in Years) 2.23± 3.97
CAPS Severity 78.58± 13.08
Comorbid Disorders
Anxiety Disorder 11 (15.50)
Mood Disorder 36 (50.70)
Alcohol/Substance Abuse Disorder 3 (4.20)
Abbreviation: CAPS, Clinician Administered PTSD scale.
aN = 71.
At post-treatment, 73% of the participants did not meet
PTSD diagnosis criteria. At follow-up, 69% no longer met
PTSD diagnosis and 31% still met the criteria. CBT had a sig-
nificant effect on the total score of the CAPS (F (2.76, 176.57)
= 94.75, P < 0.001, N2within = 0.60). The CAPS total score
significantly decreased until the end of the treatment, but
no statistical difference was observed between the post-
treatment and the follow-up. At pre-treatment, its mean
was 78.58 (SD = 13.08); at T1, 69.13 (SD = 18.36); at T2, 51.97 (SD
= 26.50); at post-treatment 33.00 (SD = 26.85); and at follow-
up of 36.68 (SD = 30.78).
The results of the repeated ANOVA for NM difficulties
(without including sleep data) indicated that the presence
of NM (frequency) [F (2.77, 171.74) = 1.59, P =.20] and NM dis-
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tress [F (2.75, 170.58) = 1.40, P =.25] before the beginning of
the CBT had no effect on PTSD symptom reduction.
In Table 2, Cochran analyses show CBT significantly re-
duced NM frequency and distress (P < 0.001). However, 15
(23.4%) participants still presented NM (more than twice a
week) at post-treatment and 14 (21.9%) at follow-up.
When assessing the impact of each CBT strategy on NM,
pairwise comparisons (McNemar tests) revealed a statis-
tically significant decrease for NM frequency between T1
and T2 up to the post-treatment, and with no significant
change afterwards (from post-treatment to follow-up). In
contrast, for NM distress, we observed a significant de-
crease from the beginning of the therapy up to T2 and no
significant change after the ninth session.
5. Discussion
Participants with NM did not benefit less from CBT
than those with fewer or no NM. Moreover, CBT had a posi-
tive impact on NM reduction with 77% of participants who
did no longer present NM after the treatment. The results
demonstrated that CBT had an effect on NM reduction at
specific stages in the course of the treatment. First, NM
frequency began to decline after practicing imaginal expo-
sure and continued to do so until the end of the therapy,
when in vivo exposure was completed. NM distress demon-
strated another trajectory with a decrease after psychoed-
ucation and diaphragmatic breathing until the end of the
imaginal exposure approach.
The impact of each CBT strategy on NM reduction is in-
teresting as each one impacted distinct aspects of NM. For
example, the rationale of diaphragmatic breathing train-
ing is to provide a way to reduce patient anxiety when
exposed to trauma-related stimuli (5). Available evidence
from past studies confirms the efficacy of anxiety manage-
ment techniques, but results are somewhat mixed in the
literature (17-20). In Miller and DiPilato (17), it was demon-
strated that progressive deep muscle relaxation training
(PDMR) was efficient in reducing the frequency and the
intensity of idiopathic NM compared to a wait-list con-
trol. Although this previous study was not conducted in
a PTSD context, recent studies revealed relationships be-
tween high levels of anxiety and NM (18), and thus relax-
ation training or diaphragmatic breathing in PTSD treat-
ment may help to reduce stress arousal generated dur-
ing NM. Additionally, Exposure, relaxation, and rescript-
ing treatment (ERRT), which directly addresses NM, uses re-
laxation and has demonstrated positive results (20). Nev-
ertheless, in a study by Vaughan et al. (19), participants
assigned to applied muscle relaxation (AMR) reported no
changes in NM frequency.
No studies have tested the impact of psychoeducation
on NM distress. As mentioned by Krakow and Zadra (21),
individuals seem to remain sceptical on the fact that NM
can be treated. Therefore, it could be hypothesized that
psychoeducation, during which information is provided
to participants on PTSD, could help address this belief and
help decrease distress associated with NM.
Finally, the goal of exposure therapy (22), in imagina-
tion or in vivo, is to help change the victim’s perception of a
situation and reaction to this specific and problematic sit-
uation by confronting fears. A few studies tried to better
understand its impact (7, 9, 23) and one (9) argued that the
efficacy of live exposure on NM (as for other PTSD symptom
reduction) might be due to an increased sense of control
over fear or distress associated with the trauma.
Although CBT was efficient in reducing NM frequency
and distress, NM were still present among 23% of the par-
ticipants after the treatment. This result is consistent with
earlier findings (7). One explanation for persistent NM af-
ter CBT is that NM lead individuals to learn to avoid them.
For example, people may adopt avoidance behaviors, such
as delayed bed time. This continued behavior can con-
tribute to maintain NM as it is not addressed by CBT (24).
Trauma survivors may develop perpetuating factors main-
taining NM and thus, NM may need to be specifically ad-
dressed in treatment (21). Clinicians have an important
role to play in the prevention and early treatment of NM
in trauma victims by monitoring them and their content
(25). There is still room for improvement for CBT as it re-
lates to NM reduction. Incorporating CBT for NM, such as
imagery rehearsal therapy (IRT) is an interesting avenue,
as studies have already shown promising results with this
approach (26). These results also call for more research in
order to identify the most efficient treatment for sleep dis-
turbances in PTSD. For example, therapy sessions may be
added if NM are still too frequent or intense. Similarly, it is
important to better understand the differential efficacy of
treating NM before, during or after CBT for PTSD.
This study had some limitations. The lack of specific
NM questionnaires with questions related to distress, such
as the nightmare distress questionnaire (NDQ) (27), and
weekly sleep diaries would have helped to better under-
stand the sleep course and to differentiate of NM content,
i.e. related to the event or not. Furthermore, it may be dif-
ficult to generalize our results as NM difficulties were not
part of the selection criteria of the study. Participants did
not consult for sleep difficulties.
In conclusion, the findings of this research suggest NM
do not impact on the CBT for PTSD, and specific therapy
components differently impacted NM frequency and dis-
tress. Future studies should examine NM, sleep mecha-
nisms and the impact of specific CBT for PTSD strategies on
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Table 2. Prevalences and Cochran Analyses for the Effect of CBT for PTSD on NM Frequency and Distressa
Variables Pre-Treatment T1 T2 Post-Treatment 6 Months Follow-Up Time Effect
X2 (4, 64) P Value
NM Frequency Presence 45 (70.31) 42 (65.63) 28 (43.75) 15 (23.44) 14 (21.88) 60.92 < 0.001
NM Distress Presence 52 (81.25) 37 (57.81) 23 (35.94) 19 (29.69) 21 (32.81) 56.75 < 0.001
Abbreviations: NM, nightmare; PTSD, post-traumatic stress disorder; T1, evaluation after psychoeducation and diaphragmatic breathing component; T2, evaluation after
imaginal exposure component.
aValues are expressed as No. %.
these variables.
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